| Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, November 2015
|
| DOI | 10.1002/cpt.269 |
| Pubmed ID | |
| Authors |
R S Gammal, M H Court, C E Haidar, O F Iwuchukwu, A H Gaur, M Alvarellos, C Guillemette, J L Lennox, M Whirl-Carrillo, S S Brummel, M J Ratain, T E Klein, B R Schackman, K E Caudle, D W Haas |
| Abstract |
The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37). We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org). This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 145 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 15% |
| Student > Master | 18 | 12% |
| Student > Ph. D. Student | 15 | 10% |
| Student > Bachelor | 13 | 9% |
| Other | 12 | 8% |
| Other | 29 | 20% |
| Unknown | 36 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 25 | 17% |
| Medicine and Dentistry | 24 | 17% |
| Biochemistry, Genetics and Molecular Biology | 23 | 16% |
| Agricultural and Biological Sciences | 13 | 9% |
| Chemistry | 3 | 2% |
| Other | 14 | 10% |
| Unknown | 43 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2023.
All research outputs
#2,626,845
of 25,837,817 outputs
Outputs from Clinical Pharmacology & Therapeutics
#463
of 4,619 outputs
Outputs of similar age
#36,032
of 299,742 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#3
of 38 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,619 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,742 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.